Ritamix Global Limited (1936.HK) Q4 2024 Earnings Report

Ritamix Global Limited delivered a resilient QQ4 2024 performance with topline expansion and a maintained gross margin in a volatile commodity environment. Revenue for the quarter stood at MYR 31.45 million, up 7.2% year over year, while gross profit reached MYR 6.689 million and gross margin remained solid at approximately 21.3%. Net income registered MYR 1.851 million, implying a net margin of about 5.88% and an earnings per share of MYR 0.0039. EBITDA was MYR 1.681 million, with an EBITDA margin of roughly 5.34% and operating margin around 4.54% (operating income MYR 1.427 million). The quarter benefited from a lean cost structure, but earnings were tempered by working capital dynamics and limited operating cash flow, as CFO was negative by MYR 1.75 million and free cash flow was negative by about MYR 1.1925 million.

The balance sheet remains robust with a substantial net cash position. Total cash and short-term investments stood at MYR 95.072 million against total debt of MYR 1.892 million, yielding a net debt position of MYR -58.429 million. Liquidity metrics are favorable: current ratio 3.97 and quick ratio 3.05, underscoring short-term financial strength. However, the company reported negative operating cash flow driven largely by working capital movements (notably receivables and inventories), signaling an opportunity to optimize working capital conversion to cash flow from operations.

Valuation metrics reflect a mature, cash-rich profile for a small-cap producer in the Consumer Defensive/Animal Nutrition space (P/E ~27.8, P/S ~6.5, P/B ~1.53). The dividend payout ratio of about 16.1% alongside a modest dividend yield (as reported) provides some income appeal, but the stock’s current valuation may imply modest growth optionality rather to the margin and cash-flow trajectory. Management commentary on the call (where available) would be central to confirming execution plans, particularly around cost control, procurement strategies, and potential capacity expansion. Given the sector dynamics, Ritamix appears to be solid on balance sheet strength with room to improve cash conversion, while revenue growth is commendable but earnings quality will hinge on working capital efficiency and cost discipline.